Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL4555190 | 0.85 | TP53 (0.31) | — | |
| SCHEMBL13227497 | 0.74 | — | — | |
| SCHEMBL1812456 | 0.72 | — | — | |
| SCHEMBL12729664 | 0.70 | — | — | |
| SCHEMBL24521370 | 0.69 | — | — | |
| SCHEMBL18462081 | 0.69 | — | — | |
| SCHEMBL20464763 | 0.69 | GAA (0.32) | GAA | |
| SCHEMBL14564582 | 0.68 | LMNA (0.45) | ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL4555321 | 0.67 | — | — | |
| SCHEMBL531292 | 0.67 | CCR2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4016663-B1 | ELECTRODE MATERIAL FOR THE PRINTING OF POLYMER BATTERIES | INNOVATIONLAB GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| WO-2019007989-A9 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019007989-A1 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-01-10 | — | — | WO | disclosed |
| EP-3424921-A1 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2019-01-09 | — | — | EP | disclosed |
| US-20170029377-A1 | SITE-SPECIFIC DYNAMIC NUCLEAR POLARIZATION NMR AGENTS | UNITED STATES DEPARTMENT OF ENERGY | 2017-02-02 | — | — | US | disclosed |
| EP-2894476-A1 | Genetically Encoded Spin Label | Universität Konstanz (DE) | 2015-07-15 | — | — | EP | disclosed |
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20120316203-A1 | Compositions and Methods for Inhibition of Cancers | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-12-13 | — | — | US | disclosed |
| US-20090318667-A1 | Peptoid compositions and methods of using the same | NEW YORK UNIVERSITY | 2009-12-24 | — | — | US | disclosed |
| WO-2009139922-A2 | PEPTOID COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| WO-2008103613-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | OTHERA HOLDING, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101195-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | OTHERA HOLDING, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20070231744-A1 | Holographic recording medium | KABUSHIKI KAISHA TOSHIBA (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316203-A1 | Compositions and Methods for Inhibition of Cancers | HCCS, GPX4, HMOX1 | KDM4E 1041/4885ALDH1A1 361/4885GAA 4775/4885 |
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | PARP1, PARP2, PARP11 | KDM4E 616/4885ALDH1A1 57/4885GAA 2359/4885 |
| US-20170029377-A1 | SITE-SPECIFIC DYNAMIC NUCLEAR POLARIZATION NMR AGENTS | ADAR, HNRNPR, ANP32A | KDM4E 3842/4885ALDH1A1 4830/4885GAA 3999/4885 |
| US-20090318667-A1 | Peptoid compositions and methods of using the same | PEPD, NGLY1, ANPEP | KDM4E 4041/4885ALDH1A1 4437/4885GAA 516/4885 |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | HDGF, HMOX1, HMOX2 | KDM4E 4017/4885ALDH1A1 161/4885GAA 3200/4885 |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | VHL, ABCC1, SLC11A2 | KDM4E 1383/4885ALDH1A1 92/4885GAA 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.